Research programme: HIV-1 protease inhibitors - Rottapharm|Madaus
Alternative Names: BRU-83-92Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Rottapharm Madaus
- Class Peptides
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Italy
- 08 Nov 2014 Preclinical development is ongoing in Italy
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda